Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.65 |
| ▸ | BCHE | P06276 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.62 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.60 |
| ▸ | HTR3B | O95264 | 1/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.60 |
| ▸ | HTR3A | P46098 | 1/20 | 0.60 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoclidine SCHEMBL1542330 | 1.00 | GLA (0.74) | GLATSHRRXFP1CYP2D6CHRNA7 | |
| Benzoclidine SCHEMBL1542430 | 1.00 | GLA (0.74) | GLATSHRRXFP1CYP2D6CHRNA7 | |
| SCHEMBL1234895 | 0.85 | CYP2D6 (0.65) | TSHRRXFP1CYP2D6CHRNA7BCHE | |
| SCHEMBL1234896 | 0.85 | CYP2D6 (0.65) | TSHRRXFP1CYP2D6CHRNA7BCHE | |
| Bicarbonate SCHEMBL1721399 | 0.83 | GLA (0.67) | GLATSHRRXFP1CYP2D6CHRNA7 | |
| Bicarbonate SCHEMBL1720584 | 0.83 | GLA (0.67) | GLATSHRRXFP1CYP2D6CHRNA7 | |
| SCHEMBL7824053 | 0.82 | CYP2D6 (0.62) | TSHRRXFP1CYP2D6CHRNA7BCHE | |
| SCHEMBL7824049 | 0.82 | CYP2D6 (0.62) | TSHRRXFP1CYP2D6CHRNA7BCHE | |
| SCHEMBL11896515 | 0.82 | GLA (0.58) | GLATSHRRXFP1CYP2D6CHRNA7 | |
| SCHEMBL8935124 | 0.81 | CHRNA7 (0.60) | GLATSHRRXFP1CHRNA7BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118638109-A | Preparation method of opium drug-oxelidine | 中山大学 | 2024-09-13 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1605939-B1 | PHARMACEUTICAL USE OF 1-AZABICYCLO¬ 2.2.2 OCTANES AND A METHOD OF TESTING COMPOUNDS FOR THE ABILITY OF ACTIVATING INACTIVE WT P53 | APREA AB (SE) | 2008-10-15 | — | — | EP | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060276502-A1 | Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53. | APREA AB (SE) | 2006-12-07 | — | — | US | claimed |
| EP-1476166-B1 | USE OF LOW MOLECULAR WEIGHT COMPOUNDS FOR PREPARING A MEDICAMENT USEFUL IN TREATING MUTANT P53 MEDIATED DISEASES | APREA AB (SE) | 2006-07-19 | — | — | EP | claimed |
| EP-1605939-A1 | PHARMACEUTICAL USE OF 1-AZABICYCLO[ 2.2.2] OCTANES AND A METHOD OF TESTING COMPOUNDS FOR THE ABILITY OF ACTIVATING INACTIVE WT P53 | APREA AB (SE) | 2005-12-21 | — | — | EP | claimed |
| US-20050090510-A1 | Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases | APREA THERAPEUTICS AB (SE) | 2005-04-28 | — | — | US | claimed |
| EP-1476166-A1 | USE OF LOW MOLECULAR WEIGHT COMPOUNDS FOR PREPARING A MEDICAMENT USEFUL IN TREATING MUTANT P53 MEDIATED DISEASES | APREA AB (SE) | 2004-11-17 | — | — | EP | claimed |
| WO-2004084893-A1 | PHARMACEUTICAL USE OF 1-AZABICYCLO[2.2.2]OCTANES AND A METHOD OF TESTING COMPOUNDS FOR THE ABILITY OF ACTIVATING INACTIVE WT P53 | APREA AB (SE) | 2004-10-07 | — | — | WO | claimed |
| WO-2003070250-A1 | USE OF LOW MOLECULAR WEIGHT COMPOUNDS FOR PREPARING A MEDICAMENT USEFUL IN TREATING MUTANT P53 MEDIATED DISEASES | APREA AB (SE) | 2003-08-28 | — | — | WO | claimed |
| US-4835162-A | 3-QUINUCLIDINYL BENZOATE OR METHYL CARBAMATE | UNIVERSITY OF ROCHESTER | 1989-05-30 | — | — | US | claimed |
| CN-118638109-B | Preparation method of opium drug-oxelidine | 中山大学 | 2025-10-28 | — | — | CN | disclosed |
| CN-118638109-B | Preparation method of opium drug-oxelidine | 中山大学 | 2025-10-28 | — | — | CN | disclosed |
| US-4966916-A | DI-AND TRIMETHYLAMINOETHYL BENZOATES, PHENYLCARBAMATES AND PHENYLTHIOCARBAMATES | UNIVERSITY OF ROCHESTER | 1990-10-30 | — | — | US | disclosed |
| EP-0347844-A2 | A translucent cosmetic emulsion | KAO CORPORATION (JP) | 1989-12-27 | — | — | EP | disclosed |
| US-4835162-A | 3-QUINUCLIDINYL BENZOATE OR METHYL CARBAMATE | UNIVERSITY OF ROCHESTER | 1989-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276502-A1 | Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53. | TP53, TP53BP1, MITF | GLA 438/4885TSHR 1582/4885RXFP1 3490/4885 |
| US-20050090510-A1 | Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases | TP53, ACP1, TP53BP1 | GLA 1144/4885TSHR 3751/4885RXFP1 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.